The impact of CpG island methylator phenotype and microsatellite instability on tumour budding in colorectal cancer

Histopathology

Volumn 61, Issue 5, 2012, Pages 777-787

  Zlobec, Inti ^a,b   Bihl, Michel P ^b   Foerster, Anja ^b   Rufle, Alex ^b   Lugli, Alessandro ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

CIMP; Colorectal cancer; Methylation; Microsatellite instability; Tumour budding

Indexed keywords

B RAF KINASE; CYTOKERATIN; K RAS PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PROGNOSIS; COLORECTAL CANCER; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PHENOTYPE; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 84868124205     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04273.x     Document Type: Article

References (33)

1. Compton CC. Pathologic prognostic factors in the recurrence of rectal cancer. Clin. Colorectal Cancer 2002; 2; 149-160.
2. Turner RR, Li C, Compton CC. Newer pathologic assessment techniques for colorectal carcinoma. Clin. Cancer Res. 2007; 13; 6871s-6876s.
3. Hase K, Shatney C, Johnson D, Trollope M, Vierra M. Prognostic value of tumour 'budding' in patients with colorectal cancer. Dis. Colon Rectum 1993; 36; 627-635.
4. Nakamura T, Mitomi H, Kanazawa H, Ohkura Y, Watanabe M. Tumour budding as an index to identify high-risk patients with stage II colon cancer. Dis. Colon Rectum 2008; 51; 568-572.
5. Ueno H, Mochizuki H, Hashiguchi Y et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004; 127; 385-394.
6. Wang LM, Kevans D, Mulcahy H et al. Tumour budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am. J. Surg. Pathol. 2009; 33; 134-141.
7. Jass JR, Barker M, Fraser L et al. APC mutation and tumour budding in colorectal cancer. J. Clin. Pathol. 2003; 56; 69-73.
8. Nosho K, Baba Y, Tanaka N et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J. Pathol. 2010; 222; 350-366.
9. Ogino S, Cantor M, Kawasaki T et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006; 55; 1000-1006.
10. Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J. Pathol. 2011; 225; 336-343.
11. Dahlin AM, Palmqvist R, Henriksson ML et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin. Cancer Res. 2010; 16; 1845-1855.
12. Zlobec I, Bihl M, Rufle A, Foerster A, Lugli A. Stratification and prognostic relevance of Jass's molecular classification of colorectal cancer. Front. Gastrointest. Cancer 2012; 2; doi: 10.3389/fonc.2012.00007.
13. Ogino S, Kawasaki T, Kirkner GJ, Suemoto Y, Meyerhardt JA, Fuchs CS. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut 2007; 56; 1564-1571.
14. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010; 138; 2088-2100.
15. Zlobec I, Lugli A. Epithelial mesenchymal transition and tumour budding in aggressive colorectal cancer: tumour budding as oncotarget. Oncotarget 2010; 1; 651-661.
16. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50; 113-130.
17. Jass JR, Atkin WS, Cuzick J et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 1986; 10; 437-459.
18. Zlobec I, Minoo P, Terracciano L, Baker K, Lugli A. Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. Histopathology 2011; 59; 482-495.
19. Perneger TV. What's wrong with Bonferroni adjustments. Br. Med. J. (Clin. Res. Ed.) 1998; 316; 1236-1238.
20. Kloor M, Michel S, von Knebel Doeberitz M. Immune evasion of microsatellite unstable colorectal cancers. Int. J. Cancer 2010; 127; 1001-1010.
21. Schwitalle Y, Kloor M, Eiermann S et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008; 134; 988-997.
22. Baker K, Chong G, Foulkes WD, Jass JR. Transforming growth factor-beta pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes. Histopathology 2006; 49; 371-380.
23. Baker K, Foulkes WD, Jass JR. MSI-H colorectal cancers preferentially retain and expand intraepithelial lymphocytes rather than peripherally derived CD8+ T cells. Cancer Immunol. Immunother. 2009; 58; 135-144.
24. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009; 28; 151-166.
25. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J. Mol. Diagn. 2008; 10; 13-27.
26. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J. Mol. Diagn. 2007; 9; 305-314.
27. Jover R, Nguyen TP, Perez-Carbonell L et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology 2011; 140; 1174-1181.
28. Kim JC, Choi JS, Roh SA, Cho DH, Kim TW, Kim YS. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas. Ann. Surg. Oncol. 2010; 17; 1767-1776.
29. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin. Cancer Res. 2003; 9; 2898-2903.
30. Ogino S, Nosho K, Kirkner GJ et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58; 90-96.
31. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002; 40; 127-132.
32. Prall F. Tumour budding in colorectal carcinoma. Histopathology 2007; 50; 151-162.
33. Prall F, Nizze H, Barten M. Tumour budding as prognostic factor in Stage I/II colorectal carcinoma. Histopathology 2005; 47; 17-24.